Company profile: Trellis Bioscience
1.1 - Company Overview
Company description
- Provider of therapeutic antibody therapies for infectious diseases and oncology, developing TRL1068 to disrupt bacterial biofilms and enhance antibiotics in prosthetic joint infections, TRL404 pan-influenza antibody cocktail, TRL3D3 targeting RSV, and TRL345 against cytomegalovirus, enabled by the CellSpot platform to discover high-affinity monoclonal antibodies from human memory B-cells.
Products and services
- CellSpot™ Platform: Proprietary technology that discovers high-affinity monoclonal antibodies from human memory B-cells, enabling discovery for various therapeutic applications
- TRL1068: Therapeutic-grade monoclonal antibody that disrupts bacterial biofilm, enhancing antibiotic effectiveness against resistant bacteria, particularly in prosthetic joint infections
- TRL404: Pan-influenza antibody cocktail targeting conserved influenza regions, effective as acute treatment against multiple strains, including H5N1 and H7N9
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Trellis Bioscience
PhosImmune
HQ: United States
Website
- Description: Provider of clinical-stage therapeutic cancer vaccines enabled by a library of unique, aberrantly phosphorylated tumor antigens (PTAs) directly implicated in metastasis, addressing the need for high-quality tumor antigens for use in new and more effective cancer vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhosImmune company profile →
Syntimmune
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology drug candidates for a wide range of autoimmune diseases, advancing differentiated therapies based on expertise in neonatal Fc receptor (FcRn) biology and its role in the pathogenesis of IgG-mediated conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syntimmune company profile →
Aridis Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel, differentiated biopharmaceutical therapies for infectious diseases, including AR-301, a fully human monoclonal antibody targeting S. aureus alpha-toxin to treat ventilator-associated pneumonia; AR-320, a long-acting antibody to prevent ventilator-associated pneumonia; AR-501, inhaled gallium citrate for bacterial lung infections in cystic fibrosis patients; and the MabIgX platform to discover rare, potent human monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aridis Pharmaceuticals company profile →
Immunovant
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical offerings focused on enabling normal lives for patients with autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunovant company profile →
Vir Biotechnology
HQ: United States
Website
- Description: Provider of immunology-based products to treat and prevent infectious diseases and other serious conditions, including Phase 2 tobevibart + elebsiran for chronic hepatitis delta and elebsiran + PEG-IFN-α for chronic hepatitis B; Phase 1 VIR-1388 for HIV prevention; and preclinical candidates VIR-8190 (RSV & hMPV), VIR-2981 (influenza A/B), and VIR-1949 (pre-cancerous HPV lesions).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vir Biotechnology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Trellis Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Trellis Bioscience
2.2 - Growth funds investing in similar companies to Trellis Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Trellis Bioscience
4.2 - Public trading comparable groups for Trellis Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →